On December 11, 2020 Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio‐delivery and biodistribution of medicines, reported that its University collaborators will be presenting three sets of research findings on MTX110 at The International Symposium on Pediatric Neuro‐Oncology on 13‐16 December 2020 in Karuizawa, Japan (to be held online this year) (Press release, Midatech Pharma, DEC 11, 2020, View Source [SID1234572861]). The first two presentations, by Columbia University Medical Center and University of Texas Health Center at Houston, are being presented for the first time. The third presentation, by the Pacific Pediatric Neuro‐Oncology Consortium, was also presented at last months’ Society of Neuro‐Oncology (SNO2020)
conference. Abstract details and links to the posters are provided below:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A Phase I Study Examining the Feasibility of Intermittent Convection‐Enhanced Delivery (CED) of MTX110 for the Treatment of Children with Newly Diagnosed Diffuse Intrinsic Midline Gliomas (ABSTRACT DDEL‐07, Page iii284*) ‐ Lead Author: Dr Stergios Zacharoulis MD, Columbia University Medical Center, New York, USA. In the study:
Patients are receiving continuous CED infusions of MTX110 for 48 hours on two cycles separated by 5 to 7 days;
3 patients have been treated so far at 30 microM;
No Serious Adverse Events;
Toxicity: Grade II diplopia (1) Grade I sensation (n=1), headache Grade II (n=2); and
1 patient progressed 8 months post treatment
The presentation may be found at: View Source;phase‐i‐study‐examining‐the‐feasibility‐ofintermittent‐ convection‐enhanced‐delivery‐ced‐of‐mtx110‐for‐the‐treatment‐of‐childr/b4b8cf89e6‐ 1607680894/mtx110‐203_dipg_trial_‐dr_stergio_zacharoulis.pdf
High Dose MTX110 (Soluble Panobinostat) Safely Administered into the Fourth Ventricle in a Non‐Human Primate Model (ABSTRACT DDEL‐09, Page iii285*) ‐ Lead Author: Dr David Sandberg MD, McGovern Medical School, University of Texas Health Center at Houston, Houston, Texas, USA. Conclusions of the presentation are:
Fourth ventricle catheters were successfully instilled to enable locoregional infusion of MTX110;
MTX110 was well‐tolerated, with no evidence of toxicity;
Drug levels in the CNS reached a therapeutic range; and
The data support the safety of administration of MTX110 via the fourth ventricle
Clinical trial in recurrent medulloblastoma patients is ongoing (NCT04315064)
The presentation may be found at: View Source;dose‐mtx110‐soluble‐panobinostat‐safelyadministered‐ into‐the‐fourth‐ventricle‐in‐a‐non‐human‐primate‐model/df48e55757‐ 1607683538/mtx110_preclinical_safety_‐dr_david_sandberg.pdf
PNOC015: An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection‐Enhanced Delivery (CED) in Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated with External Beam Radiation Therapy (ABSTRACT EPCT‐12, Page iii306*) Lead Author: Dr Sabine Mueller, Pacific Pediatric Neuro‐Oncology Consortium
The presentation may be found at: View Source;an‐open‐label‐single‐arm‐study‐of‐mtx110‐ delivered‐by‐convection‐enhanced‐delivery‐ced‐in‐patients‐with‐diffuse‐intrins/ee47f281a6‐1607683490/mtx110‐ 201_dipg_trial_‐dr_sabine_mueller.pdf
* Abstracts from the 19th International Symposium on Pediatric Neuro‐Oncology (ISPNO 2020), December 13‐16, 2020.
Neuro‐Oncology, Volume 22, Supplement 3 may be found at:
View Source
Commenting, Steve Damment, EVP R&D of Midatech, said: "These presentations by Midatech’s University collaborators
provide useful data points for our MTX110 programmes; the Columbia study in DIPG uses an implantable and
programmable pump to infuse drug without the need for repeated surgery, unlike the system deployed in the UCSF study
we recently reported; and, the Texas pre‐clinical safety study demonstrates the feasibility of fourth ventricle infusion, the
method of administration for our ongoing Phase I pilot study in recurrent medulloblastoma patients."
About MTX110
MTX110 is a water‐soluble form of panobinostat free base, achieved through complexation with hydroxypropyl‐β‐ cyclodextrin (HPBCD), that enables convection‐enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non‐selective histone deacetylase inhibitor (panHDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak) is not suitable for treatment of brain cancers owing to poor blood‐brain barrier penetration and inadequate brain drug concentrations. Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD‐27). MTX110 is delivered directly into and around the patient’s tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood‐brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticance